(Q50044950)

English

A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer.

scientific article published on 21 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

1 reference

based on heuristic

inferred from title

Salmonella typhi

object named as

Salmonella Typhi

1 reference

based on heuristic

inferred from title

Alejandrina Vendrell

1

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

Marcela F. Pasetti

3

object named as

Marcela F Pasetti

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

author name string

María J Gravisaco

2

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

Máximo Croci

4

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

Lucas Colombo

5

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

Carla Rodríguez

6

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

Claudia Mongini

7

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

Claudia I Waldner

8

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

language of work or name

0 references

publication date

21 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

29

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

4

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

728-736

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Tumors as elusive targets of T-cell-based active immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Cancer immunotherapy based on killing of Salmonella-infected tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Can engineered bacteria help control cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Attenuated bacteria as effectors in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Immune surveillance and anti-tumor immune responses: an anatomical perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Characterization of the immunophenotype and the metastatic properties of a murine T-lymphoma cell line. Unexpected expression of cytoplasmatic CD4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Immunoregulatory T cells in tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

The critical role of type-1 innate and acquired immunity in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

The innate immune response differs in primary and secondary Salmonella infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Intra-tumoral Salmonella typhimurium induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

IFN-gamma-mediated survival enables human neutrophils to produce MCP-1/CCL2 in response to activation by TLR ligands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

The intriguing role of polymorphonuclear neutrophils in antitumor reactions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Human neutrophils produce interferon gamma upon stimulation by interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Tolerance, not immunity, crucially depends on IL-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Regulatory T cells in human disease and their potential for therapeutic manipulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

Bacterial perturbation of cytokine networks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.017

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.11.017

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/21095252

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50044950&oldid=1799555958"